Investigated O
for O
use/treatment O
in O
cancer/tumors B-NEG
( O
unspecified O
) O
, O
lung B-NEG
cancer I-NEG
, O
myelodysplastic B-NEG
syndrome I-NEG
, O
and O
prostate B-NEG
cancer I-NEG
. O

-DOCSTART- O

Chronic B-NEG
Renal I-NEG
Failure I-NEG

-DOCSTART- O

Heroin O
is O
a O
mu-opioid O
agonist O
. O

It O
acts O
on O
endogenous O
mu-opioid O
receptors O
that O
are O
spread O
in O
discrete O
packets O
throughout O
the O
brain O
, O
spinal O
cord O
and O
gut O
in O
almost O
all O
mammals O
. O

Heroin O
, O
along O
with O
other O
opioids O
, O
are O
agonists O
to O
four O
endogenous B-DNP
neurotransmitters I-DNP
. O

They O
are O
beta-endorphin O
, O
dynorphin O
, O
leu-enkephalin O
, O
and O
met-enkephalin O
. O

The O
body O
responds O
to O
heroin O
in O
the O
brain O
by O
reducing O
( O
and O
sometimes O
stopping O
) O
production B-NEU
of I-NEU
the I-NEU
endogenous I-NEU
opioids I-NEU
when O
heroin O
is O
present O
. O

Endorphins O
are O
regularly O
released O
in O
the O
brain B-DNP
and O
nerves B-NEU
, O
attenuating B-NEG
pain I-NEG
. O

Their O
other O
functions O
are O
still O
obscure O
, O
but O
are O
probably O
related O
to O
the O
effects O
produced O
by O
heroin O
besides O
analgesia O
( O
antitussin O
, O
anti-diarrheal O
) O
. O

-DOCSTART- O

breast B-NEG
abscess I-NEG
; O
abscess B-NEG
of O
breast O
; O
acute B-NEG
mastitis I-NEG

-DOCSTART- O

galactostasis B-NEG
; O
hypogalactia B-NEG
; O
scant B-NEG
breast I-NEG
; O
inadequacy B-NEG
of O
lactation O

-DOCSTART- O

absorption O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
motility O
. O

-DOCSTART- O

abdominal B-NEG
pain I-NEG
due O
to O
stagnation O
of O
Gi O

-DOCSTART- O

Weak O
stomach O
qi O
, O
noise B-NEG
in I-NEG
stomach I-NEG
, O
diarrhea B-NEG
, O
stagnation B-NEG
of I-NEG
water I-NEG
, O
dry B-NEG
vomiting I-NEG
, O
annoyment B-NEG

-DOCSTART- O

the O
upper O
emaciation B-NEG
; O
lung B-NEG
diabetes I-NEG

-DOCSTART- O

To O
induce O
diaphoresis B-NEG
, O
to O
ease O
the O
mind B-DNP
, O
and O
to O
relieve O
fever B-NEG
. O

-DOCSTART- O

diabetics B-NEG
due O
to O
interior O
heat B-NEU

-DOCSTART- O

Yokukansan O
inhibits O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
: O
the O
role O
of O
a O
A-adrenoceptor B-DNP
. O

-DOCSTART- O

To O
replenish O
blood B-DNP
, O
activate O
circulation B-DNP
and O
regulate O
menstruation B-NEU
. O

-DOCSTART- O

Damp-heat B-NEG
dysentery I-NEG
, O
enteritis B-NEG
and O
diarrhea B-NEG
. O

-DOCSTART- O

profuse B-NEG
nasal I-NEG
bleeding I-NEG
; O
brandy B-NEG
nose I-NEG
; O
rosacea B-NEG

-DOCSTART- O

Ipilimumab O
blocks O
the O
CTLA-4 B-NEU
inhibitory I-NEU
signal I-NEU
, O
and O
allows O
the O
Cytotoxic O
T O
lymphocytes O
to O
destroy O
the O
cancer B-DNP
cells I-DNP
. O

Fotemustine O
alkylates O
guanine O
by O
forming O
chloroethyl O
adducts O
at O
the O
6 O
position O
of O
guanine O
, O
resulting O
in O
N1-guanine O
and O
N3-cytosine O
cross O
linkages O
, O
inhibition O
of O
DNA B-NEU
synthesis I-NEU
, O
cell B-DNP
cycle I-DNP
arrest I-DNP
, O
and O
finally O
apoptosis B-NEU
. O

-DOCSTART- O

move O
Gi(Qi O
) O
and O
blood B-NEU

-DOCSTART- O

Carcinoma B-NEG
, I-NEG
Renal I-NEG
Cell I-NEG

-DOCSTART- O

Yin O
Chen O
Hao O
Tang O
, O
a O
Chinese O
prescription O
, O
inhibits O
both O
herpes B-NEG
simplex I-NEG
virus I-NEG
type-1 I-NEG
and I-NEG
type-2 I-NEG
infections O
in O
vitro O
. O

-DOCSTART- O

close O
sores B-NEG

-DOCSTART- O

ecchymosis B-NEG

-DOCSTART- O

Methotrexate O
anti-tumor O
activity O
is O
a O
result O
of O
the O
inhibition O
of O
folic B-DNP
acid I-DNP
reductase I-DNP
, O
leading O
to O
inhibition O
of O
DNA B-NEU
synthesis I-NEU
and O
inhibition O
of O
cellular B-NEU
replication I-NEU
. O

Golimumab O
inhibits O
the O
activity B-NEU
of I-NEU
the I-NEU
cytokine I-NEU
, O
tumor B-DNP
necrosis I-DNP
factor I-DNP
alpha I-DNP
. O

-DOCSTART- O

Type B-NEG
2 I-NEG
Diabetes I-NEG
Mellitus I-NEG

-DOCSTART- O

Treatment O
of O
fever B-NEG
due O
to O
deficiency O
of O
yin O
, O
consumptive B-NEG
fever I-NEG
, O
fever B-NEG
in O
infantile O
malnutrition O
. O

-DOCSTART- O

In O
countries O
with O
high O
rates O
of O
hepatitis B-NEG
B I-NEG
infection I-NEG
, O
vaccination O
of O
newborns O
has O
not O
only O
reduced O
the O
risk O
of O
infection B-NEG
, O
but O
has O
also O
led O
to O
marked O
reduction O
in O
liver B-NEG
cancer I-NEG
. O

-DOCSTART- O

Symptoms O
of O
menopause B-NEG
. O

-DOCSTART- O

swelling B-NEG
of O
carbuncle B-NEG

-DOCSTART- O

move O
stasis B-NEG

-DOCSTART- O

The O
ingredients O
of O
this O
prescription O
are O
all O
bitter O
in O
taste O
and O
cold O
in O
nature O
, O
so O
that O
the O
fire O
purging O
and O
detoxifying B-POS
effect I-POS
is O
very O
strong O
. O

Since O
the O
bitter-cold O
drugs O
are O
liable O
to O
damage O
yin-energy O
, O
the O
prescription O
is O
only O
used O
for O
cases O
when O
the O

-DOCSTART- O

To O
clear O
heat B-NEU
and O
eliminate O
pus B-NEG
. O

-DOCSTART- O

Blood B-NEU
activation I-NEU
and O
injury B-NEG
healing O

-DOCSTART- O

To O
soothe O
liver B-DNP
and O
clear O
heat B-NEU
; O
To O
constrain O
qi O
and O
strengthen O
spleen B-DNP
; O
To O
calm O
spirit B-DNP

-DOCSTART- O

post B-NEU
delivery I-NEU
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Woman O
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Hypersensitivity B-NEG
, O
motility B-NEU
, O
Others O
, O
Body B-NEU
weight I-NEU
, O
Protective B-NEU
immunity I-NEU
, O
Quality O
of O
life O
, O
Hemostatic B-NEU
function I-NEU
, O
Inflammation B-NEG

-DOCSTART- O

To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver B-DNP
, O
spleen B-DNP
and O
stomach B-DNP
, O
and O
to O
resolve O
phlegm B-NEG
. O

-DOCSTART- O

Rheumatoid B-NEG
Arthritis I-NEG

-DOCSTART- O

sweating O
head O
; O
perspiration B-NEG
on O
forehead O
; O
morbid O
perspiration B-NEG
on O
the O
head O

-DOCSTART- O

Chronic B-NEG
ulcers I-NEG
. O
Dragon's O
blood B-DNP
( O
Xuejie O
) O
is O
used O
with O
Frankincense O
( O
Ruxiang O
) O
and O
Myrrh O
( O
Moyao O
) O
for O
external O
use O
. O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
chronic B-NEG
coughing I-NEG
and O
inflammation B-NEG
in O
urination O
. O

-DOCSTART- O

Metabolic O
urinary O
profiling O
of O
alcohol B-NEG
hepatotoxicity I-NEG
and O
intervention O
effects O
of O
Yin O
Chen O
Hao O
Tang O
in O
rats O
using O
ultra-performance O
liquid O
chromatography/electrospray O
ionization O
quadruple O
time-of-flight O
mass O
spectrometry O
. O

-DOCSTART- O

delirium B-NEG

-DOCSTART- O

Bone B-DNP
metabolism/density I-DNP
, O
Intelligence B-POS
, O
Bone B-DNP
Health I-DNP
and O
Osteoporosis B-NEG
, O
Overall O
CVD B-NEG
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Others O
, O
Mental B-DNP
state I-DNP
and O
performance O

-DOCSTART- O

Tropicamide O
acts O
by O
blocking O
the O
responses O
of O
the O
iris B-DNP
sphincter I-DNP
muscle I-DNP
to O
the O
iris B-DNP
and I-DNP
ciliary I-DNP
muscles I-DNP
to O
cholinergic B-NEU
stimulation I-NEU
, O
producing O
dilation B-NEU
of O
the O
pupil O
and O
paralysis B-NEG
of O
the O
ciliary O
muscle O
. O

Hydroxyamphetamine O
is O
a O
sympathomimetic O
drug O
, O
that O
is O
, O
a O
drug O
that O
stimulates O
the O
sympathetic B-DNP
nervous I-DNP
system I-DNP
as O
an O
agonist O
of O
human O
TAAR1 O
. O

-DOCSTART- O

Used O
as O
an O
analgesic O
adjunct O
in O
anesthesia B-NEG
and O
as O
a O
primary O
anesthetic O
drug O
in O
procedures O
requiring O
assisted O
ventilation O
and O
in O
the O
relief O
of O
pain B-NEG
. O

-DOCSTART- O

Didanosine O
is O
converted O
to O
the O
active O
triphosphate O
form O
, O
which O
is O
incorporated O
into O
DNA O
and O
inhibits O
DNA O
elongation O
. O

-DOCSTART- O

Endocrine B-DNP
system I-DNP
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP
, O
Others O

-DOCSTART- O

restrain O
Aconiti B-NEG
Tuber I-NEG

-DOCSTART- O

Inecalcitol O
is O
an O
analogue O
of O
calcitriol O
, O
the O
naturally O
active O
metabolite O
of O
vitamin O
D O
. O

Calcitriol O
and O
their O
analogues O
activate O
the O
vitamin B-DNP
D I-DNP
receptor I-DNP
( O
VDR B-DNP
) O
. O

Vitamin O
D O
has O
a O
major O
role O
in O
regulating O
calcium B-NEU
absorption I-NEU
from O
the O
gut O
, O
storage O
in O
mineral O
form O
in O
the O
bones O
, O
and O
excretion B-NEU
by O
the O
kidney O
and O
effectively O
prevents O
rickets B-NEG
in O
infants O
. O

Vitamin O
D O
and O
calcitriol O
can O
cause O
hypercalcemia B-NEG
at O
high O
or O
frequently O
repeated O
doses O
; O
in O
turn O
, O
hypercalcemia B-NEG
can O
cause O
kidney B-NEG
toxicity I-NEG
by O
accumulation O
of O
calcium-containing O
micro-crystals O
and O
heart B-NEG
and I-NEG
muscle I-NEG
dysfunction I-NEG
by O
impairing O
contractions O
. O

The O
mechanism O
of O
action O
is O
currently O
unknown O
, O
but O
it O
is O
proposed O
that O
inecalcitol O
exerts O
its O
superagonistic O
action O
through O
enhancing O
coactivator O
binding O
by O
the O
VDR O
. O

-DOCSTART- O

promote O
the O
stomach B-DNP
and O
increased O
food O
intake O

-DOCSTART- O

edema B-NEG
edema B-NEG
, O
pathogenesis O
of O
which O
is O
associated O
with O
dysfunction B-NEG
of I-NEG
the I-NEG
lung I-NEG
, I-NEG
spleen I-NEG
and I-NEG
kidney I-NEG
. O

-DOCSTART- O

Lidocaine O
alters O
signal O
conduction O
in O
neurons B-DNP
by O
blocking O
the O
fast O
voltage O
gated O
sodium O
( O
Na+ O
) O
channels O
in O
the O
neuronal O
cell B-DNP
membrane I-DNP
that O
are O
responsible O
for O
signal O
propagation O
. O

Ceftriaxone O
works O
by O
inhibiting B-POS
the I-POS
mucopeptide I-POS
synthesis I-POS
and O
results O
in O
the O
formation O
of O
defective O
cell O
walls O
and O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

Knee B-NEG
Osteoarthritis I-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Woman O
, O
Quality O
of O
life O
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
General O
woman O
, O
Inflammation B-NEG
, O
Others O
, O
Hemostatic O
function O

-DOCSTART- O

For O
clearing O
heat B-NEU
and O
removing O
toxic B-NEG
substances I-NEG

-DOCSTART- O

Used O
to O
produce O
controlled B-NEG
hypotension I-NEG
during O
surgical O
procedures O
and O
in O
hypertensive B-NEG
crises I-NEG
. O

-DOCSTART- O

Airway O
Reflexes O
, O
Protective O

-DOCSTART- O

ulcer B-NEG

-DOCSTART- O

Cardiovascular B-NEG
Diseases I-NEG

-DOCSTART- O

nourish O
bone B-DNP
marrow I-DNP

-DOCSTART- O

Fenretinide O
treatment O
may O
cause O
ceramide B-NEG
to O
build O
up O
in O
tumor B-DNP
cells I-DNP
and O
is O
associated O
with O
the O
accumulation O
of O
reactive B-NEU
oxygen I-NEU
species I-NEU
, O
resulting O
in O
cell B-NEU
death I-NEU
through O
apoptosis B-NEU
and/or O
necrosis B-NEU
. O

Sodium O
butyrate O
( O
NaB O
) O
, O
a O
short O
chain O
fatty O
acid O
, O
is O
a O
HDAC O
inhibitor O
and O
induces O
growth B-NEU
arrest I-NEU
and O
apoptosis B-NEU
in O
a O
variety O
of O
human O
cancer O
cells O
. O

-DOCSTART- O

Malignancy B-NEG

-DOCSTART- O

The O
authors O
report O
the O
3 O
months' O
treatment O
of O
51 O
cases O
of O
breast O
proliferation O
disease B-NEG
with O
modified O
Xiao O
Yao O
San O
and O
Er O
Chen O
decoction O
, O
an O
effective O
rate O
being O
0.961 O
. O
In O
each O
patient O
before O
and O
after O
treatment O
, O
saliva O
estradiol B-DNP
( O
SE2 B-DNP
) O
, O
saliva O
progesterone B-DNP
( O
SP B-DNP
) O
, O
saliva O
testosterone B-DNP
( O
ST B-DNP
) O
and O
plasma O
prolactin B-DNP
( O
PRL B-DNP
) O
concentrations O
were O
monitored O
and O
breast O
molybdenum-target O
X-ray O
films O
were O
taken O
. O

The O
results O
showed O
that O
after O
treatment O
, O
SE2 B-DNP
concentrations O
declined O
very O
significantly O
(P O
less O
than O
0.001 O
) O
; O
SP B-DNP
concentrations O
declined O
significantly O
(P O
less O
than O
0.05 O
) O
; O
PRL B-DNP
concentrations O
declined O
very O
significantly O
(P O
less O
than O
0.005 O
) O
, O
but O
ST B-DNP
concentrations O
did O
not O
change O
significantly O
. O

Breast O
molybdenum-target O
X-ray O
films O
showed O
absorption O
of O
proliferation O
masses O
in O
21 O
cases O
. O

These O
indicated O
that O
the O
medicine O
could O
regulate O
endocrine B-DNP
system I-DNP
, O
perhaps O
through O
suppressing O
secretion B-NEU
of I-NEU
PRL I-NEU
, O
decreasing O
prolactin B-NEU
antagonist I-NEU
action I-NEU
to O
follicular B-DNP
stimulating I-DNP
hormone I-DNP
so O
as O
to O
restore O
follicle B-NEU
function I-NEU
, O
and O
could O
regulate O
pituitary-follicle O
axis O
and O
make O
the O
axis O
normal O
. O

-DOCSTART- O

1 O
Inhibiting O
the O
growth O
of O
leukemia615 B-NEG
, O
sarcoma180 B-NEG
and O
cervial B-NEG
carcinoma14 I-NEG
in O
mice O
. O
2 O
Relieving O
iodine B-NEG
deficiency I-NEG
and O
goiter B-NEG
in O
experimental O
animals O
. O

-DOCSTART- O

Treatment O
of O
carbuncle O
, O
boil B-NEG
and O
other O
pyogenic B-NEG
infections I-NEG
of O
the O
skin O
, O
sore B-NEG
throat I-NEG
, O
scrofula B-NEG
, O
constipation B-NEG
. O

-DOCSTART- O

a O
disease O
that O
has O
watery B-NEG
and I-NEG
chronic I-NEG
defecation I-NEG

-DOCSTART- O

wind-heat B-NEG
; O
wind B-NEG
and O
heat B-NEU
; O
wind-heat B-NEG
pathogene O
wind B-NEG
and O
heat B-NEG
blended O
as O
a O
pathogenic O
factor O
. O

-DOCSTART- O

Parkinson B-NEG
Disease I-NEG

-DOCSTART- O

Lenalidomide O
inhibits O
TNF-alpha B-NEU
production I-NEU
, O
stimulates O
T B-DNP
cells I-DNP
, O
reduces O
serum B-NEU
levels I-NEU
of I-NEU
the I-NEU
cytokines I-NEU
vascular I-NEU
endothelial I-NEU
growth I-NEU
factor I-NEU
( O
VEGF O
) O
and O
basic O
fibroblast O
growth O
factor O
( O
bFGF O
) O
, O
and O
inhibits O
angiogenesis O
. O

-DOCSTART- O

vigilance O
, O
Physical B-DNP
performance I-DNP
and O
fitness O
, O
Endurance O
, O
activation O
, O
attention O
, O
energy B-DNP
supply I-DNP
and O
recovery O
, O
Metabolism B-DNP
, O
sleep B-DNP
, O
Memory B-DNP
, O
Arousal B-DNP
, O
Others O
, O
Mental B-DNP
state I-DNP
and O
performance O

-DOCSTART- O

Myocardial B-NEG
Reperfusion I-NEG
Injury I-NEG

-DOCSTART- O

Similar O
to O
zidovudine O
, O
efavirenz O
inhibits O
the O
activity B-NEU
of I-NEU
viral I-NEU
RNA-directed I-NEU
DNA I-NEU
polymerase I-NEU
( O
i.e O
. O
, O
reverse B-DNP
transcriptase I-DNP
) O
. O

Antiviral O
activity O
of O
efavirenz O
is O
dependent O
on O
intracellular O
conversion O
to O
the O
active O
triphosphorylated O
form O
. O

The O
rate O
of O
efavirenz O
phosphorylation O
varies O
, O
depending O
on O
cell O
type O
. O

It O
is O
believed O
that O
inhibition O
of O
reverse B-DNP
transcriptase I-DNP
interferes O
with O
the O
generation B-NEU
of I-NEU
DNA I-NEU
copies I-NEU
of I-NEU
viral I-NEU
RNA I-NEU
, O
which O
, O
in O
turn O
, O
are O
necessary O
for O
synthesis O
of O
new O
virions O
. O

Intracellular O
enzymes O
subsequently O
eliminate O
the O
HIV B-DNP
particle I-DNP
that O
previously O
had O
been O
uncoated O
, O
and O
left O
unprotected O
, O
during O
entry O
into O
the O
host O
cell O
. O

Thus O
, O
reverse O
transcriptase O
inhibitors O
are O
virustatic O
and O
do O
not O
eliminate O
HIV B-DNP
from O
the O
body O
. O

Even O
though O
human O
DNA O
polymerase O
is O
less O
susceptible O
to O
the O
pharmacologic O
effects O
of O
triphosphorylated O
efavirenz O
, O
this O
action O
may O
nevertheless O
account O
for O
some O
of O
the O
drug's O
toxicity O
. O

-DOCSTART- O

Mild O
Asthma B-NEG

-DOCSTART- O

To O
arrest O
spontaneous O
emission O
, O
to O
reduce O
excessive B-NEG
urination I-NEG
, O
and O
to O
cure O
turbid B-NEG
discharge I-NEG
from I-NEG
the I-NEG
urethra I-NEG
. O
cturnal B-NEG
emission I-NEG
, O
spermatorrhea B-NEG
, O
enuresis B-NEG
, O
frequent B-NEG
urination I-NEG
, O
turbid B-NEG
discharge I-NEG
with I-NEG
urine I-NEG
. O

-DOCSTART- O

irregular O
chills B-NEG
and O
fever B-NEG

-DOCSTART- O

1.To O
promote O
blood B-DNP
circulation I-DNP
and O
remove O
blood B-NEG
stasis I-NEG
, O
expel O
wind B-NEG
and O
alleviate O
pain B-NEG
. O
2 O
To O
relieve O
asthma B-NEG
. O

-DOCSTART- O

night B-NEU
sweat I-NEU
; O

night B-NEU
sweating I-NEU
spontaneous O
sweating B-NEU
during O
asleep O
and O
no B-NEU
sweating I-NEU
while O
awake O
, O
chiefly O
caused O
by O
deficiency O
of O
vital O
essence O
and O
presence O
of O
internal B-NEG
heat I-NEG
. O

-DOCSTART- O

Japanese O
herbal O
( O
Kampo O
) O
medicine O
, O
Hochuekkito O
( O
Bu-Zhong-Yi-Qi-Tang O
in O
Chinese O
, O
TJ-41 O
) O
and O
Juzentaihoto O
( O
Shi-Quan-Da-Bu-Tang O
in O
Chinese O
, O
TJ-48 O
) O
are O
well-known O
Kampo O
formulas O
used O
as O
tonic O
. O

Although O
these O
medicines O
have O
separately O
been O
applied O
to O
the O
patients O
clinically O
depending O
on O
their O
symptoms O
, O
the O
differences O
of O
the O
pharmacological O
activities O
for O
these O
medicines O
have O
not O
been O
fully O
understood O
. O

TJ-48 O
and O
TJ-41 O
were O
compared O
for O
their O
effects O
on O
antibody B-DNP
response O
in O
upper O
respiratory O
mucosal B-DNP
immune I-DNP
system I-DNP
in O
vivo O
. O

Oral O
administration O
of O
TJ-41 O
( O
100 O
mg O
kg(-1 O
) O
per O
day O
) O
to O
early O
aged O
BALB/c O
mice O
, O
which O
were O
nasally O
sensitized O
with O
influenza O
hemagglutinin O
vaccine O
, O
significantly O
enhanced O
influenza O
virus-specific O
IgA B-DNP
and I-DNP
IgG I-DNP
antibody I-DNP
titers O
in O
nasal O
cavity O
and O
sera O
, O
respectively O
. O

However O
, O
oral O
administration O
of O
TJ-48 O
( O
100 O
mg O
kg(-1 O
) O
per O
day O
) O
failed O
to O
show O
the O
enhancing O
activity O
. O

TJ-41 O
increased O
not O
only O
influenza O
virus-specific O
IgA B-DNP
antibody I-DNP
titer O
but O
also O
total O
IgA B-DNP
antibody I-DNP
titer O
in O
nasal O
cavity O
. O

The O
stimulating O
activity O
of O
TJ-41 O
disappeared O
after O
treatment O
with O
methotrexate O
. O

The O
present O
study O
strongly O
suggests O
that O
TJ-41 O
can O
stimulate O
the O
mucosal B-DNP
immune I-DNP
system I-DNP
of O
upper O
respiratory O
tract O
, O
and O
results O
in O
enhancement O
of O
antigen-specific O
antibody B-DNP
response O
in O
upper O
respiratory O
mucosal B-DNP
and I-DNP
systemic I-DNP
immune I-DNP
systems I-DNP
. O

-DOCSTART- O

developmemt O
of O
manic B-NEG
syndrome I-NEG

-DOCSTART- O

discharge O
heat B-NEU
and O
cool O
blood B-DNP

-DOCSTART- O

For O
stablizing O
period O
, O
controlling O
urine B-NEU
and O
reducing O
heavy B-NEG
blood-flow I-NEG

-DOCSTART- O

1 O
To O
reduce O
heat B-NEU
caused O
by O
deficient O
yin O
; O
2 O
To O
clear O
heat B-NEU
in O
infants O
caused O
by O
malnutrition B-NEG

-DOCSTART- O

penis B-NEG
ulceration I-NEG

-DOCSTART- O

For O
activating O
blood B-DNP
and O
reducing O
pain B-NEG
. O

-DOCSTART- O

sudden O
turmoil B-NEG
; O
cholera B-NEG
disease I-NEG
; O
acute B-NEG
gastroenteritis I-NEG
; O
acute B-NEG
vomiting I-NEG
and O
diarrhea B-NEG
a O
group O
of O
diseases O
including O
cholera B-NEG
, O
characterized O
by O
sudden O
and O
drastic B-NEG
vomiting I-NEG
and O
diarrhea B-NEG
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
remove O
obstruction O
from O
the O
channels O
and O
to O
remove O
heat B-NEU
from O
blood O
and O
cause O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

To O
calm O
the O
liver O
and O
suppress O
the O
asthenic B-NEG
yang O
, O
to O
promote O
the O
restoration O
of O
consciousness O
, O
decrease O
blood B-NEU
pressure I-NEU
. O

-DOCSTART- O

Vaginal O
Atrophy O

-DOCSTART- O

The O
itching B-NEG
sensation I-NEG
due O
to O
eczema B-NEG

-DOCSTART- O

Ureterostomy O
; O
Functional B-NEG
Disturbance I-NEG

-DOCSTART- O

To O
regulate O
the O
flow O
of O
qi O
and O
blood B-NEU
, O
to O
relieve O
cough B-NEG
, O
and O
to O
induce O
tranquilization B-POS
. O

-DOCSTART- O

boil B-NEG
in O
the O
throat O

-DOCSTART- O

Allosteric O
interactions O
between O
central O
benzodiazepine O
receptors O
and O
gamma-aminobutyric O
acid O
( O
GABA O
) O
receptors O
potentiate O
the O
effects O
of O
GABA O
. O

-DOCSTART- O

To O
break O
d O
and O
move O
phlegm B-NEG
, O
harmonize O
stomach B-DNP
and O
disperse O
accumulation O
. O

-DOCSTART- O

breast O
abscess O
; O
acute O
mastitis O

-DOCSTART- O

To O
remove O
heat B-NEU
and O
counteract O
toxicity B-NEG
, O
to O
nourish O
liver B-DNP
and O
stomach B-DNP
, O
curing O
sore B-NEG
, O
to O
improve O
consciousness B-POS
, O
to O
tonify B-POS
the I-POS
body I-POS
. O

-DOCSTART- O

The O
previous O
experimental O
studies O
have O
demonstrated O
that O
addition O
of O
Huang O
Qi O
( O
[symbol O
: O
see O
text] O
Radix O
Astragali O
) O
to O
the O
formulated O
recipe O
Sheng O
Mai O
Yin O
( O
[symbol O
: O
see O
text] O
Decoction O
for O
Pulse-activation O
) O
exerts O
the O
effects O
of O
strengthening O
the O
myodynamia B-POS
, O
increasing O
the O
coronary B-DNP
flow I-DNP
, O
improving O
myocardial B-DNP
metabolism I-DNP
, O
and O
resisting O
the O
arrhythmia B-NEG
. O

The O
active O
component O
of O
Huang O
Lian O
( O
[symbol O
: O
see O
text] O
Rhizoma O
Coptidis O
) O
can O
prolong O
the O
myocardial B-NEU
action I-NEU
potential O
and O
antagonize O
the O
chloroform- O
, O
aconitine- O
, O
barium O
chloride- O
, O
epinephrine- O
or O
coronary O
ligation-induced O
arrhythmia B-NEG
by O
blocking O
the O
calcium O
channel O
. O

Ku O
Shen O
( O
[symbol O
: O
see O
text] O
Radix O
Sophorae O
Flavescentis O
) O
contains O
matrine O
and O
flavones O
, O
which O
act O
as O
quinidine O
to O
decrease O
the O
excitability B-NEU
of I-NEU
the I-NEU
myocardium I-NEU
, O
prolong O
the O
refractory O
period O
, O
and O
inhibit O
the O
ectopic B-NEG
cardiac I-NEG
rhythm I-NEG
. O

And O
Dan O
Shen O
( O
[symbol O
: O
see O
text] O
Radix O
Salviae O
Miltiorrhizae O
) O
has O
the O
action O
of O
improving O
the O
ischemic B-NEG
state I-NEG
of O
the O
myocardium B-DNP
by O
dilating O
the O
coronary B-NEU
vessels I-NEU
. O

In O
conclusion O
, O
the O
definite O
therapeutic O
effects O
of O
Huang O
Lian O
Sheng O
Mai O
Yin O
in O
treating O
ventricular B-NEG
, I-NEG
atrial I-NEG
and I-NEG
nodal I-NEG
arrhythmia I-NEG
suggests O
that O
the O
prescription O
is O
rational O
and O
accords O
with O
the O
therapeutic O
principle O
of O
TCM O
. O

Except O
discomfort B-NEG
in O
the O
gastric B-DNP
cavity I-DNP
and O
poor O
appetite B-NEU
experienced O
by O
some O
patients O
, O
there O
is O
no O
toxic O
or O
adverse O
reaction O
. O

-DOCSTART- O

hemoptysis B-NEG

-DOCSTART- O

Baker's B-NEG
Cyst I-NEG

-DOCSTART- O

To O
relieve O
muscle B-DNP
; O
To O
clear O
heat B-NEU
, O
To O
accelerate O
rash B-NEG
, O
To O
stop O
cough B-NEG

-DOCSTART- O

Its O
decoction O
inhibits O
the O
development O
of O
egg-white O
induced O
arthritis B-NEG
in O
mice O
. O

-DOCSTART- O

Esophageal B-NEG
Varices I-NEG

-DOCSTART- O

a O
continuum O
of O
pus B-NEG
and O
blood B-NEG
due O
to O
the O
parasite O
in O
the O
ear O

-DOCSTART- O

Hepatitis B-NEG
B I-NEG
Virus I-NEG

-DOCSTART- O

relieve O
heat B-NEU
and O
dissipate O
stasis B-NEG

-DOCSTART- O

Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Mood O

-DOCSTART- O

Dim O
vision O
, O
flooding B-NEG
and O
spotting B-NEG
, O
bleeding B-NEG
due O
to O
external B-NEG
injury I-NEG
, O
sore O
toxin B-NEG
and O
intractable O
lichen B-NEG
. O

-DOCSTART- O

For O
tonifying O
weakness B-NEG
. O

-DOCSTART- O

vomiting B-NEG
due O
to O
heat B-NEG
in I-NEG
the I-NEG
stomach I-NEG

-DOCSTART- O

An O
active O
component O
pachyman O
promotes O
macrophage B-DNP
phagocytosis I-DNP
in O
mice O
, O
and O
enhances O
lymphocyte-blastogensis B-DNP
rate O
in O
vitro O
. O

Preventing O
the O
formation O
of O
gastric B-NEG
ulcer I-NEG
under O
stress B-NEG
in O
rats O
. O

Diuretic B-NEU
and O
liver-protective B-POS
. O

-DOCSTART- O

promote O
the O
small O
intestine B-DNP

-DOCSTART- O

Prostate B-NEG
Cancer I-NEG

-DOCSTART- O

Treament O
of O
chronic B-NEG
bronchitis I-NEG
. O

-DOCSTART- O

To O
regulate O
qi O
, O
promote O
blood B-NEU
circulation I-NEU
and O
regulate O
menstruation B-NEU
. O

-DOCSTART- O

Lymphoma B-NEG

-DOCSTART- O

Unspecified B-NEG
Childhood I-NEG
Solid I-NEG
Tumor I-NEG
, I-NEG
Protocol I-NEG
Specific I-NEG

-DOCSTART- O

Neostigmine O
is O
used O
for O
the O
symptomatic O
treatment O
of O
myasthenia B-NEG
gravis I-NEG
by O
improving O
muscle B-NEU
tone I-NEU
. O

-DOCSTART- O

Regulation O
of O
qi O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
Respiratory B-DNP
systems I-DNP
, O
Respiratory B-DNP
systems I-DNP
health I-DNP
, O
motility B-NEU
, O
absorption B-NEU
, O
Others O
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

Objectives O
Mycobacterium O
avium O
subspecies O
paratuberculosis B-NEG
( O
MAP O
) O

-DOCSTART- O

Treatment O
of O
chronic B-NEG
rheumatiod I-NEG
arthritis I-NEG
with O
numbness B-NEG
and O
ankylosis B-NEG
, O
hemiplegia B-NEG
in O
stroke O
, O
convulsion B-NEG
, O
tetanus B-NEG
, O
leprosy B-NEG
, O
scabies B-NEG
, O
scrofula B-NEG
with O
suppuration B-NEG
. O

-DOCSTART- O

amenorrhea B-NEG
; O
menstrual B-NEG
block I-NEG
absence O
or O
suppression B-NEG
of I-NEG
menstruation I-NEG
. O

-DOCSTART- O

nourish O
Eum(Yin O
) O
and O
nourish O
blood B-DNP

-DOCSTART- O

inability B-NEG
to O
turn O
over O

-DOCSTART- O

cool O
the O
blood B-DNP
and O
move O
the O
blood B-DNP

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Quality O
of O
life O
, O
Endocrine B-DNP
system I-DNP
, O
Others O
, O
Memory B-POS
, O
Protective O
immunity B-NEU
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

bluish O
blindness B-NEG
; O
optic B-NEG
atrophy I-NEG
; O
glaucoma B-NEG

-DOCSTART- O

Locally O
acting O
as O
an O
irritant O
for O
skin O
and O
mucosa O
; O
orally O
as O
a O
potent O
purgative O
. O

-DOCSTART- O

break O
hard O
mass O
and O
dissipate O
accumulation O

-DOCSTART- O

reinforce O
bone O
marrow O

-DOCSTART- O

Dalbavancin O
has O
a O
spectrum O
and O
mechanism O
of O
action O
similar O
to O
vancomycin O
, O
a O
naturally O
formed O
glycopeptide O
antimicrobial O
. O

-DOCSTART- O

disperse O
cold B-NEG

-DOCSTART- O

phthisical O
cough B-NEG
due O
to O
Eum O
deficiency O

-DOCSTART- O

Atopic B-NEG
Dermatitis I-NEG

-DOCSTART- O

As O
first O
clinical O
data O
indicate O
, O
the O
achieved O
blood B-NEU
pressure I-NEU
reduction O
was O
particularly O
pronounced O
in O
the O
early O
morning O
when O
the O
vaccine O
effect O
suppressed O
the O
naturally O
occurring O
morning O
rise O
in O
blood B-NEU
pressure I-NEU
. O

-DOCSTART- O

In O
order O
to O
better O
understand O
the O
characteristics O
of O
atmospheric O
carbonaceous O
aerosol O
at O
a O
background O
site O
in O
Northeast O
Asia O
, O
semicontinuous O
organic O
carbon O
( O
OC O
) O
and O
elemental O
carbon O
( O
EC O
) O
, O
and O
time-resolved O
water-soluble O
organic O
carbon O
( O
WSOC O
) O
were O
measured O
by O
a O
Sunset O
OC O
/ O
EC O
and O
a O
PILB-TOC O
( O
particle-into-liquid O
sampler O
coupled O
with O
an O
online O
total O
organic O
carbon O
) O
analyzer O
, O
respectively O
, O
at O
the O
Gosan O
supersite O
on O
Jeju O
Island O
, O
Korea O
, O
in O
the O
summer O
( O
May O
42914 O
17 O
) O
and O
fall O
( O
August O
43002 O
30 O
) O
of O
2009 O
. O

Hourly O
average O
OC O
concentration O
varied O
in O
the O
range O
of O
approximately O
0.87-28.38 O
microgC O
m-3 O
, O
with O
a O
mean O
of O
4.07+/- O
2.6 O
microgC O
m-3 O
, O
while O
the O
hourly O
average O
EC O
concentration O
ranged O
approximately O
from O
0.04 O
to O
8.19 O
. O

microgC O
m-3 O
, O
with O
a O
mean O
of O
1.35 O
+/- O
0.71 O
microgC O
m-3 O
, O
from O
May O
28 O
to O
June O
17 O
, O
2009 O
. O
During O
the O
fall O
season O
, O
OC O
varied O
in O
the O
approximate O
range O
0.9-9.6 O
microgC O
m-3 O
, O
with O
a O
mean O
of O
2.3 O
+/-0.80 O
microgC O
m-3 O
, O
whereas O
EC O
ranged O
approximately O
from O
0.01 O
to O
5.4 O
microgC O
m-3 O
, O
with O
a O
mean O
of O
0.66 O
+/- O
0.38 O
microgC O
m-3 O
. O
Average O
contributions O
of O
EC O
to O
TC O
and O
WSOC O
to O
OC O
were O
0.26 O
+/- O
0.097 O
and O
0.206 O
+/-7.4% O
, O
and O
0.376 O
+/- O
0.235 O
and O
0.572 O
+/- O
0.222 O
during O
summer O
and O
fall O
seasons O
, O
respectively O
. O
As O
expected O
, O
clear O
diurnal O
variation O
of O
WSOC/OC O
was O
found O
in O
summer O
, O
varying O
from O
0.22 O
during O
the O
nighttime O
up O
to O
0.72 O
during O
the O
daytime O
, O
mainly O
due O
to O
the O
photo-oxidation O
process O
. O

In O
order O
to O
investigate O
the O
effect O
of O
air O
mass O
pathway O
on O
the O
characteristics O
of O
carbonaceous O
aerosol O
, O
5-day O
back-trajectory O
analysis O
was O
conducted O
using O
the O
HYSPLIT O
model O
. O
The O
air O
mass O
pathways O
were O
classified O
into O
four O
types O
: O
Continental O
( O
CC O
) O
, O
Marine O
( O
M O
) O
, O
East O
Sea O
( O
ES O
) O
and O
Korean O
Peninsula O
( O
KP O
) O
. O

The O
highest O
OC/EC O
ratio O
of O
3.63 O
was O
observed O
when O
air O
mass O
originated O
from O
the O
Continental O
area O
( O
CC O
) O
. O

The O
lowest O
OC/EC O
ratio O
of O
0.79 O
was O
measured O
when O
air O
mass O
originated O
from O
the O
Marine O
area O
( O
M O
) O
. O

A O
high O
OC O
concentration O
was O
occasionally O
observed O
at O
Gosan O
due O
to O
local O
biomass O
burning O
activities O
. O

The O
contribution O
of O
secondary O
OC O
to O
total O
OC O
varied O
approximately O
between O
0.084 O
and O
0.322 O
and O
depended O
on O
air O
mass O
type O
. O

-DOCSTART- O

To O
clear O
heat B-NEU
and O
dampness B-NEG
, O
promote O
blood B-NEG
circulation I-NEG
and O
remove O
blood B-NEG
stasis I-NEG
: O
For O
jaundice B-NEG
of O
dampness-heat O
type O
and O
abdominal B-NEG
mass I-NEG
. O
Recently O
used O
for O
acute B-NEG
and I-NEG
chronic I-NEG
hepatitis I-NEG
, O
cirrhosis B-NEG
, O
cholecysitis B-NEG
, O
etc O
. O
, O
also O
for O
diarrhea B-NEG
, O
desentery B-NEG
and O
leucorrhagia B-NEG
of O
dampness-heat O
type O
, O
ough O
of O
lung-heat B-NEU
type O
, O
sorethroat B-NEG
, O
silicosis B-NEG
, O
and O
tumors B-NEG
such O
as O
lung B-NEG
cancer I-NEG
, O
nasopharyngeal B-NEG
carcinoma I-NEG
, O
chorionic B-NEG
epithelioma I-NEG
, O
tumor B-NEG
of O
the O
digestive O
tract O
, O
etc O
. O
2 O
To O
stop O
bleeding B-NEG
. O
For O
hematemesis B-NEG
, O
hemafecia B-NEG
, O
hemoptysis B-NEG
and O
epistaxis B-NEG
. O
External O
use O
for O
bleeding B-NEG
after O
trauma B-NEG
and O
after O
separation O
of O
umbilical O
cord O
in O
infants O
. O

-DOCSTART- O

bleeding B-NEG
before O
defecation O

-DOCSTART- O

To O
drain O
the O
pus B-NEG
, O
eradicate O
toxicity B-NEG
, O
eliminate O
the O
dead B-NEG
tissue I-NEG
and O
promote O
the O
growth B-NEU
of I-NEU
new I-NEU
tissue I-NEU
. O

-DOCSTART- O

To O
clear O
heat B-NEU
and O
resolve O
toxin B-NEG
, O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEG
. O

-DOCSTART- O

To O
nourish O
blood B-DNP
and O
consolidate O
the O
yin O
; O

To O
pacify O
the O
liver B-DNP
and O
stop O
pain B-NEG
; O

To O
soothe O
liver O
yang O

-DOCSTART- O

calm O
the O
fetus O

-DOCSTART- O

Swelling B-NEG
pain I-NEG
in O
joints O
, O
numbness B-NEG
in O
limbs O
, O
knocks B-NEG
and O
falls B-NEG
, O
cough B-NEG
and O
asthma B-NEG
, O
heat B-NEG
strangury I-NEG
, O
poisonous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

For O
desolving O
phlegm B-NEG
, O
stopping O
cougth B-NEG
, O
and O
soothing O
breathing B-NEU

-DOCSTART- O

Used O
in O
surgical O
procedures O
where O
a O
rapid O
onset O
and O
brief O
duration O
of O
muscle O
relaxation O
is O
needed O
( O
includes O
intubation O
, O
endoscopies O
, O
and O
ECT O
) O

-DOCSTART- O

scrofula B-NEG
; O

tuberculosis B-NEG
of O
the O
cervical O
lymphic O
node O

-DOCSTART- O

black B-DNP
hair I-DNP

-DOCSTART- O

For O
stablizing O
period O
, O
controlling O
urine B-NEU
and O
reducing O
heavy B-NEU
blood-flow I-NEU

-DOCSTART- O

Blood B-DNP
activation O
and O
injury B-NEG
healing O

-DOCSTART- O

malaria B-NEG
; O
malarial B-NEG
disorder I-NEG
malaria B-NEG
and O
other O
disease O
characterized O
by O
intermittent B-NEG
rigor I-NEG
, O
high B-NEG
fever I-NEG
and O
sweating B-NEU
. O

-DOCSTART- O

absorption B-NEU
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-POS
, O
motility O
, O
Evacuation B-NEU

-DOCSTART- O

Dextromethorphan O
is O
an O
opioid-like O
drug O
that O
binds O
to O
and O
acts O
as O
antagonist O
to O
the O
NMDA O
glutamatergic O
receptor O
, O
and O
targets O
the O
serotonin O
reuptake O
pump O
. O

-DOCSTART- O

Fluoxetine O
is O
an O
antidepressant O
belonging O
to O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
class O
, O
and O
blocks O
the O
reuptake B-NEU
of I-NEU
serotonin I-NEU
at O
the O
serotonin O
reuptake O
pump O
of O
the O
neuronal O
membrane O
, O
enhancing O
the O
actions B-NEU
of I-NEU
serotonin I-NEU
on O
5HT<sub>1A</sub> O
autoreceptors O
. O

Venlafaxine O
and O
its O
active O
metabolite O
, O
O-desmethylvenlafaxine O
( O
ODV O
) O
, O
inhibit O
the O
reuptake B-NEU
of I-NEU
both I-NEU
serotonin I-NEU
and I-NEU
norepinephrine I-NEU
with O
a O
potency O
greater O
for O
the O
5-HT O
than O
for O
the O
NE O
reuptake O
process O
. O

Quetiapine's O
antipsychotic O
activity O
is O
likely O
due O
to O
a O
combination O
of O
antagonism O
at O
D2 O
receptors O
in O
the O
mesolimbic O
pathway O
and O
5HT2A O
receptors O
in O
the O
frontal O
cortex O
. O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
palpitation B-NEG
and O
severe B-NEG
palpitation I-NEG
. O

-DOCSTART- O

relieve O
stasis B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

fetal O
leakage O

-DOCSTART- O

Patients O
with O
squamous B-NEG
cell I-NEG
carcinoma I-NEG
of I-NEG
the I-NEG
head I-NEG
and I-NEG
neck I-NEG
. O

-DOCSTART- O

Clindamycin O
inhibits O
bacterial B-NEG
protein I-NEG
synthesis I-NEG
by O
binding O
to O
bacterial O
50S O
ribosomal O
subunits O
. O

-DOCSTART- O

Acute B-NEG
Adrenal I-NEG
Insufficiency I-NEG

-DOCSTART- O

deficiency B-NEG
of O
the O
kidney O
; O
deficiency B-NEG
syndrome I-NEG
of O
the O
kidney O
the O
pathological O
changes O
due O
to O
deficiency B-NEG
of O
the O
kidney O
essence O
, O
usually O
characterized O
by O
dizziness B-NEG
, O
tinnitus B-NEG
, O
lumbago B-NEG
, O
nocturnal B-NEG
emission I-NEG
, O
impotence B-NEG
, O
lassitude B-NEG
, O
forgetfulness B-NEG
. O

-DOCSTART- O

Sudden O
stroke O
and O
fulminant O
reversal O
, O
pain B-NEG
in O
heart O
and O
abdomen B-NEG
, O
postpartum O
blood B-NEG
dizziness I-NEG
, O
child O
fright B-NEG
epilepsy I-NEG
, O
wind B-NEG
impediment O
and O
lumbago B-NEG
. O

-DOCSTART- O

The O
symptom O
of O
disease O
where O
the O
skin B-NEG
turns I-NEG
yellow I-NEG
because O
dampness O
and O
heat O
tangle O
together O

-DOCSTART- O

tinnitus B-NEG

-DOCSTART- O

promote O
all O
vessels B-DNP

-DOCSTART- O

To O
stablize O
liver B-DNP
and O
suppress O
dizziness B-NEG
; O
To O
soothe O
neck O
and O
wake-up O
brain O

-DOCSTART- O

cough B-NEG
with O
blood B-NEU
due O
to O
a O
damaged B-NEG
lungs I-NEG
because O
of O
exhaustion B-NEG
syndrome I-NEG

-DOCSTART- O

-DOCSTART- O

For O
stablizing O
period O
, O
controlling B-NEU
urine I-NEU
and O
reducing O
heavy B-NEG
blood-flow I-NEG

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
parkinson's B-NEG
disease I-NEG
. O

-DOCSTART- O

Kidney B-DNP
Transplantation O

-DOCSTART- O

steaming B-NEG
bone I-NEG
disorder I-NEG

-DOCSTART- O

ulceration B-NEG
in O
the O
gum O

-DOCSTART- O

promote O
menstruation B-NEU

-DOCSTART- O

Ticarcillin's O
antibiotic O
properties O
arise O
from O
its O
ability O
to O
prevent O
cross-linking O
of O
peptidoglycan O
during O
cell B-DNP
wall I-DNP
synthesis I-DNP
when O
the O
bacteria O
tries O
to O
divide O
, O
causing O
death O
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Physical B-POS
performance I-POS
and O
fitness B-POS
, O
Endocrine B-DNP
system I-DNP
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Strength B-POS
and O
power B-POS
, O
Others O
, O
Protective O
immunity B-NEU
, O
Hemostatic B-POS
function I-POS
, O
Metabolism B-NEU
, O
Man O

-DOCSTART- O

strengthen O
the O
teeth B-DNP

-DOCSTART- O

Quality O
of O
life O
, O
Others O

-DOCSTART- O

Chronic B-NEG
Kidney I-NEG
Disease I-NEG

-DOCSTART- O

For O
the O
treatment O
of O
chronic O
gouty B-NEG
arthritis I-NEG
when O
complicated O
by O
frequent O
, O
recurrent O
acute O
attacks O
of O
gout B-NEG
. O

-DOCSTART- O

Effect O
of O
Hachimijiogan O
( O
HJ O
) O
on O
dopamine B-DNP
( O
DA B-DNP
) O
, O
serotonin B-DNP
( O
5-HT B-DNP
) O
and O
vasoactive B-DNP
intestinal I-DNP
peptide I-DNP
( O
VIP B-DNP
) O
was O
examined O
in O
plasma O
and O
hypothalamic O
tissue O
of O
sulpiride-induced O
hyperprolactinemic O
rats O
( O
SHR O
) O
. O

Similar O
to O
bromocriptine O
( O
BR O
) O
, O
HJ O
, O
in O
combination O
with O
sulpiride O
, O
suppressed O
plasma B-NEU
prolactin I-NEU
levels I-NEU
raised O
by O
sulpiride O
alone O
. O

Furthermore O
, O
HJ O
, O
together O
with O
sulpiride O
, O
increased O
plasma B-NEU
DA I-NEU
levels I-NEU
decreased O
by O
sulpiride O
alone O
, O
while O
5-HT B-DNP
in O
plasma O
was O
increased O
by O
sulpiride O
and O
HJ O
, O
individually O
or O
in O
combination O
. O

However O
, O
plasma B-NEU
VIP I-NEU
levels I-NEU
were O
under O
detection O
limits O
on O
some O
occasions O
after O
HJ O
treatment O
. O

Successively O
, O
DA B-NEU
, I-NEU
5-HT I-NEU
and I-NEU
VIP I-NEU
levels I-NEU
in O
the O
hypothalamus O
were O
determined O
. O

Similar O
to O
the O
effect O
caused O
by O
BR O
, O
DA B-NEU
and I-NEU
5-HT I-NEU
levels I-NEU
in O
hypothalamic O
tissue O
reduced O
by O
sulpiride O
alone O
were O
also O
significantly O
increased O
by O
HJ O
together O
with O
sulpiride O
, O
while O
VIP B-NEU
levels I-NEU
were O
sometimes O
under O
detection O
levels O
with O
or O
without O
HJ O
. O

These O
results O
suggest O
that O
HJ O
stimulates O
the O
hypothalamus O
to O
increase O
DA B-DNP
and O
5-HT B-DNP
in O
SHR O
, O
providing O
evidence O
for O
the O
clinical O
efficiency O
of O
HJ O
in O
combating O
hyperprolactinemia B-NEG
. O

The O
effect O
of O
HJ O
on O
VIP B-DNP
in O
plasma O
or O
hypothalamic O
tissue O
is O
, O
however O
, O
questionable O
. O

-DOCSTART- O

nourish O
Gi(Qi O
) O
and O
blood B-DNP

-DOCSTART- O

To O
stimulate O
digestion B-NEU
and O
promote O
the O
functional O
activity O
of O
the O
stomach B-DNP
; O
to O
improve O
the O
normal O
flow O
of O
qi O
and O
dissipate O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

Infertility B-NEG

-DOCSTART- O

Alzheimer's B-NEG
Disease I-NEG

-DOCSTART- O

Other O
system B-DNP
health I-DNP
, O
Others O

-DOCSTART- O

1 O
Sennoside O
A O
is O
the O
component O
for O
purgation O
. O
2 O
. O
Promoting O
biliary B-DNP
secretion I-DNP
and O
enhancing O
the O
amount O
of O
bilirubin B-DNP
and O
bile B-DNP
acid I-DNP
. O
3 O
. O
Rhein O
and O
Emodin O
exert O
bacteriostatic O
effect O
by O
inhibting O
the O
synthesis B-DNP
of I-DNP
DNA I-DNP
, O
RNA O
and O
protein O
in O
bacteria O
4 O
. O
Emodin O
is O
a O
component O
for O
hypotensive B-NEG
5 O
. O
Oral O
use O
of O
its O
extract O
reduces O
the O
raio O
of O
serum B-DNP
cholesterol I-DNP
and O
total O
phospholipid B-DNP
in O
rabbits O
with O
hypercholesterolemia B-NEG
. O
6 O
. O
Chrysophanol O
, O
an O
other O
active O
component O
, O
exerts O
a O
hemostatic B-POS
effect I-POS
. O

-DOCSTART- O

Hemostatic O
. O

-DOCSTART- O

This O
is O
a O
syndrome O
that O
the O
both O
cheeks O
of O
children O
turn O
red O
. O

-DOCSTART- O

Methotrexate B-DNP
anti-tumor I-DNP
activity I-DNP
is O
a O
result O
of O
the O
inhibition O
of O
folic B-DNP
acid I-DNP
reductase I-DNP
, O
leading O
to O
inhibition O
of O
DNA B-NEU
synthesis I-NEU
and O
inhibition O
of O
cellular B-NEU
replication I-NEU
. O

Tretinoin O
binds O
to O
and O
activates O
retinoic B-DNP
acid I-DNP
receptors I-DNP
( O
RARs B-DNP
) O
, O
thereby O
inducing O
changes B-NEU
in I-NEU
gene I-NEU
expression I-NEU
that O
lead O
to O
cell B-NEU
differentiation I-NEU
, O
decreased O
cell B-NEU
proliferation I-NEU
, O
and O
inhibition O
of O
tumorigenesis B-NEG
. O

Mercaptopurine O
inhibits O
nucleotide B-NEU
interconversions I-NEU
and O
de B-NEU
novo I-NEU
purine I-NEU
synthesis I-NEU
, O
thereby O
blocking O
the O
formation B-NEU
of I-NEU
purine I-NEU
nucleotides I-NEU
and O
inhibiting O
DNA B-NEU
synthesis I-NEU
. O

Idarubicin O
intercalates O
into O
DNA B-NEU
and O
interferes O
with O
the O
activity B-NEU
of I-NEU
topoisomerase I-NEU
II I-NEU
, O
thereby O
inhibiting O
DNA B-NEU
replication I-NEU
, O
RNA B-NEU
transcription I-NEU
and O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

brighten O
the O
eyes B-DNP

-DOCSTART- O

To O
promote O
blood B-NEU
circulation I-NEU
to O
remove O
blood B-NEG
stasis I-NEG
, O
soothe O
the O
liver B-DNP
and O
remove O
the O
obstruction B-NEG
in O
the O
channels O
. O

-DOCSTART- O

The O
mechanism O
of O
action O
and O
receptor O
for O
PCK3145 O
suggests O
PCK3145 O
to O
be O
a O
signal O
transduction O
inhibitor O
with O
multiple O
ways O
( O
apoptosis B-NEU
, O
anti-angiogenesis B-NEU
and O
anti-metastasis B-NEU
) O
to O
restrict O
disease B-NEG
development I-NEG
. O

-DOCSTART- O

Ulcer B-NEG

-DOCSTART- O

Numbness B-NEG
of I-NEG
the I-NEG
extremities I-NEG
, O
aching O
of O
the O
joints O
and O
menstrual B-NEG
disorders I-NEG
due O
to O
deficiency B-NEG
of I-NEG
blood I-NEG
. O

-DOCSTART- O

Extemal O
use O
for O
carbuncle B-NEG
, O
pyogenic B-NEG
infection I-NEG
of O
skin O
, O
ulcera B-NEG
tive I-NEG
gingivitis I-NEG
and O
dental B-NEG
caries I-NEG
. O

Recently O
, O
also O
for O
carcinoma B-NEG
of I-NEG
breast I-NEG
, O
cervix O
and O
pancreas O
and O
malignant B-NEG
lymphoma I-NEG

-DOCSTART- O

damage B-NEG
of I-NEG
kidney I-NEG

-DOCSTART- O

leukorrhea B-NEG
with O
pruritis B-NEG
vulva I-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Quality O
of O
life O
, O
Inflammation B-NEG
, O
Protective O
immunity B-NEU
, O
Others O

-DOCSTART- O

Pneumonia B-NEG
, I-NEG
Pneumocystis I-NEG
Carinii I-NEG

-DOCSTART- O

purge O
heat B-NEU
and O
treat O
gam(gan B-NEG
) O

-DOCSTART- O

promote O
the O
stomach B-DNP
and O
disperse O
food O

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
cataracts B-NEG
, O
eye B-NEG
disorders I-NEG
/ I-NEG
infections I-NEG
, O
glaucoma B-NEG
, O
and O
macular B-NEG
degeneration I-NEG
. O

-DOCSTART- O

Methyclothiazide O
appears O
to O
block O
the O
active O
reabsorption B-NEU
of I-NEU
chloride I-NEU
and O
possibly O
sodium O
in O
the O
ascending O
loop O
of O
Henle O
, O
altering O
electrolyte O
transfer O
in O
the O
proximal O
tubule O
. O

Pargyline O
is O
a O
monoamine O
oxidase O
B O
( O
MAO-B O
) O
inhibitor O
with O
antihypertensive O
properties O
. O

-DOCSTART- O

To O
invigorate O
blood B-DNP
and O
stop O
pain B-NEG
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
a O
fever B-NEG
, O
shortness B-NEG
of I-NEG
breath I-NEG
, O
irritability B-NEG
and O
restlessness B-NEG
, O
mania B-NEG
derange I-NEG
due O
to O
blocked B-NEG
chest I-NEG
and O
diaphragm B-NEG
. O

It O
has O
a O
sever O
pain B-NEG
when O
pushing O
. O

-DOCSTART- O

blood-heat B-NEU

-DOCSTART- O

Rituximab O
binds O
to O
the O
CD20 O
antigen O
on O
B O
lymphocytes O
, O
while O
the O
Fc O
domain O
recruits O
antibodies O
and O
complements O
to O
mediate O
cell O
lysis O
and O
interferes O
with O
the O
growth O
and O
spread O
of O
cancer B-NEG
cells O
in O
the O
body O
. O

-DOCSTART- O

External O
use O
for O
vitiligo B-NEG
and O
alpecia B-NEG
areata I-NEG
. O

-DOCSTART- O

It O
is O
designed O
to O
mimic O
the O
molecular O
shape O
of O
adrenaline O
. O

It O
binds O
to O
alpha-adrenergic O
receptors O
in O
the O
nasal O
mucosa O
. O

Here O
it O
can O
, O
therefore O
, O
cause O
vasoconstriction B-NEU

-DOCSTART- O

For O
calming O
liver B-DNP
and O
containing O
wind B-NEG

-DOCSTART- O

Benzodiazepines O
, O
in O
this O
way O
, O
block O
the O
cortical O
and O
limbic O
arousal O
that O
occurs O
following O
stimulation O
of O
the O
reticular O
pathways O
. O

-DOCSTART- O

frequent O
urination B-NEU

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
Physical B-DNP
performance I-DNP
and O
fitness O
, O
absorption B-NEU
, O
Strength O
and O
power O
, O
Liver B-DNP
health I-DNP
, O
Inflammation B-NEG
, O
Liver B-DNP
, O
Others O
, O
motility B-NEG

-DOCSTART- O

jaundice B-NEG
a O
morbid O
condition O
clinically O
characterized O
by O
yellow-brown B-DNP
pigmentation I-DNP
of O
the O
skin O
and O
sclera O
and O
dark O
yellow O
colored O
urine B-DNP
, O
and O
classified O
into O
two O
types O
, O
Yang O
jaundice B-NEG
and O
Eum O
jaundice B-NEG
; O
one O
of O
the O
five O
types O
of O
jaundice B-NEG
. O

-DOCSTART- O

regurgitation B-NEG
; O
frequent O
vomiting B-NEG

-DOCSTART- O

Treatment O
of O
cough B-NEG
, O
itching B-NEG
of O
the O
throat O
and O
profuse O
expectoration B-NEG
in O
colds B-NEG
, O
nausea B-NEG
, O
vomiting B-NEG
and O
epigastric B-NEG
distension I-NEG
caused O
by O
improper O
diet O
or O
excessive O
drinking O
. O

-DOCSTART- O

Oxcarbazepine O
produces O
blockade B-DNP
of I-DNP
voltage-sensitive I-DNP
sodium I-DNP
channels I-DNP
, O
resulting O
in O
stabilization O
of O
hyperexcited O
neural B-DNP
membranes I-DNP
, O
inhibition O
of O
repetitive B-NEU
neuronal I-NEU
firing I-NEU
, O
and O
diminution O
of O
propagation B-NEU
of I-NEU
synaptic I-NEU
impulses I-NEU
. O

These O
actions O
are O
thought O
to O
be O
important O
in O
the O
prevention O
of O
seizure B-NEG
spread I-NEG
in O
the O
intact O
brain O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-NEG
pain I-NEG
is O
thought O
to O
involve O
voltage-gated B-DNP
N-type I-DNP
calcium I-DNP
ion I-DNP
channels I-DNP
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent B-DNP
calcium I-DNP
channel I-DNP
in O
the O
central O
nervous O
system O
. O

-DOCSTART- O

anhidrosis B-NEG
; O
adiaphoria B-NEG
; O
adiaphoresis B-NEG

-DOCSTART- O

Treatment O
of O
chills B-NEG
, O
fever B-NEG
and O
headache B-NEG
in O
colds B-NEG
and O
influenza B-NEG
, O
vexation B-NEG
, O
oppressed B-NEG
feeling I-NEG
in O
the O
chest O
and O
insomnia B-NEG
. O

-DOCSTART- O

wind B-NEG
Pi I-NEG
syndrome I-NEG
; O
arthralgia B-NEG
due O
to O
wind B-NEG
arthritis I-NEG
mainly O
due O
to O
pathogenic B-NEG
wind I-NEG
, O
marked O
by O
swelling B-NEG
and O
migratory B-NEG
pain I-NEG
in O
the O
joints O
of O
the O
limbs O
. O

-DOCSTART- O

Neurocognitive O
Function O
. O

-DOCSTART- O

pricking B-NEG
pain I-NEG

-DOCSTART- O

free O
the O
kidney B-DNP
and O
water O

-DOCSTART- O

Treatment O
of O
deficiency B-NEG
condition I-NEG
of I-NEG
the I-NEG
kidney I-NEG
marked O
by O
lumbago B-NEG
and O
lack O
of O
strength O
, O
threatened B-NEG
abortion I-NEG
, O
hypertension B-NEG
. O

-DOCSTART- O

kill O
worms B-NEG

-DOCSTART- O

jaundice B-NEG
a O
morbid O
condition O
clinically O
characterized O
by O
yellow-brown B-NEG
pigmentation I-NEG
of O
the O
skin O
and O
sclera O
and O
dark B-NEG
yellow I-NEG
colored I-NEG
urine I-NEG
, O
and O
classified O
into O
two O
types O
, O
Yang B-NEG
jaundice I-NEG
and O
Eum B-NEG
jaundice I-NEG
; O

one O
of O
the O
five O
types O
of O
jaundice B-NEG
. O

-DOCSTART- O

This O
study O
was O
conducted O
to O
evaluate O
the O
importance O
of O
intraoperative O
smear O
examinations O
for O
the O
final O
diagnosis O
of O
intracerebral O
stereotaxic O
procedures O
. O

125 O
consecutive O
patients O
with O
suspect O
intracerebral O
lesions B-NEG
underwent O
stereotaxic O
frame-based O
biopsies O
after O
acquisition O
of O
computer O
tomographic O
and O
magnetic O
resonance O
images O
. O

After O
secondary O
image O
processing O
, O
including O
multiplanar O
visualization O
of O
the O
target O
region O
and O
target O
definition O
, O
a O
serial O
biopsy O
was O
realized O
using O
an O
aspiration O
Sedan O
needle O
. O

Biopsy O
taking O
was O
repeated O
as O
long O
as O
pathological O
tissue O
samples O
were O
obtained O
according O
to O
the O
visual O
impression O
of O
the O
neurosurgeon O
( O
group O
I) O
or O
to O
the O
first O
neuropathological O
result O
of O
a O
smear O
examination O
( O
group O
II O
) O
. O

Retrospective O
analysis O
of O
all O
cases O
showed O
that O
intraoperative O
microscopic O
diagnostics O
could O
improve O
the O
conditions O
for O
a O
definitive O
neuropathological O
diagnosis O
from O
0.918 O
( O
56/61 O
patients O
, O
group O
I) O
to O
0.969 O
( O
62/64 O
patients O
, O
group O
II O
) O
( O
t>0.05 O
) O
. O

The O
number O
of O
biopsy O
specimens O
and O
the O
rate O
of O
CT-detectable O
small O
bleedings O
differed O
slightly O
between O
both O
groups O
and O
were O
higher O
in O
group O
II O
. O

The O
duration O
of O
surgery O
and O
anaesthesia O
as O
well O
as O
the O
final O
neurological O
outcomes O
were O
comparable O
in O
both O
groups O
. O

In O
conclusion O
, O
intraoperative O
smear O
examination O
as O
a O
kind O
of O
bedside O
diagnostics O
confers O
a O
better O
diagnostic O
safety O
and O
improves O
the O
reliability O
of O
this O
minimal O
invasive O
manoeuvre O
. O

-DOCSTART- O

To O
replenish O
the O
kidney B-DNP
and O
subdue O
hyperactivity O
of O
the O
liver B-DNP
. O

-DOCSTART- O

GSK716155 O
, O
a O
GLP-1 O
receptor O
agonist O
, O
has O
been O
shown O
to O
have O
multiple O
physiologic O
activities O
in O
the O
central O
nervous O
system O
and O
gastrointestinal O
system O
that O
could O
lower O
A1C O
. O

It O
increases O
peripheral B-NEU
glucose I-NEU
uptake I-NEU
, O
enhances O
insulin B-NEU
secretion I-NEU
, O
decreases O
glucagon B-NEU
secretion I-NEU
, O
delays O
gastric B-NEU
emptying I-NEU
, O
reduces O
food B-NEU
intake I-NEU
and O
induces O
satiety B-NEU
at O
CNS O
. O

-DOCSTART- O

loosen O
the O
chest B-DNP

-DOCSTART- O

Neck B-NEG
bone I-NEG
problems I-NEG
and O
inflammation B-NEG

-DOCSTART- O

Angiotensin B-DNP
II I-DNP
is O
a O
small O
hormone O
in O
the O
body O
and O
part O
of O
the O
RAS O
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation O
, O
Woman O
, O
Reproductive B-DNP
systems I-DNP
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Endocrine B-DNP
system I-DNP
, O
Bone B-DNP
Health I-DNP
and O
Osteoporosis B-NEG
, O
Quality O
of O
life O
, O
Menopausal B-NEG
woman O
, O
Eldery O
, O
Liver B-DNP
health I-DNP
, O
Metabolism B-DNP
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Bone B-DNP
metabolism/density I-DNP
, O
Memory B-POS
, O
Liver B-DNP
, O
Others O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Man O

-DOCSTART- O

For O
promoting O
diuresis B-NEU
and O
desolving O
inflammation B-NEG

-DOCSTART- O

The O
anti-inflammatory O
effects O
of O
diclofenac O
are O
believed O
to O
be O
due O
to O
inhibition O
of O
both O
leukocyte O
migration O
and O
the O
enzyme B-DNP
cylooxygenase I-DNP
( O
COX-1 B-DNP
and O
COX-2 B-DNP
) O
, O
leading O
to O
the O
peripheral O
inhibition O
of O
prostaglandin B-DNP
synthesis I-DNP
. O

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
angioedema B-NEG
. O

-DOCSTART- O

Delta1-dihydrotestosterone O
binds O
to O
the O
androgen O
receptor O
, O
a O
nuclear O
receptor O
which O
binds O
the O
androgenic O
hormones O
testosterone O
and O
dihydrotestosterone O
. O

-DOCSTART- O

a O
disease O
with O
pain B-NEG
in O
the O
joints O

-DOCSTART- O

Blood B-DNP
activation O
and O
injury B-POS
healing I-POS

-DOCSTART- O

Appears O
to O
preferentially O
bind O
to O
mycobacterial O
DNA O
leading O
to O
disruption O
of O
the O
cell B-NEU
cycle I-NEU
and O
eventually O
kills O
the O
bacterium O
. O

-DOCSTART- O

Lupus B-NEG
Nephritis I-NEG

-DOCSTART- O

scabies B-NEG

-DOCSTART- O

To O
calm O
asthma B-NEG
, O
dispel O
wind B-NEG
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

1 O
Applicable O
to O
summer B-NEG
fever I-NEG
in O
children O
manifested O
as O
prolonged B-NEG
fever I-NEG
, O
restlessness B-NEG
, O
thirst B-NEG
, O
fatigue B-NEG
, O
red B-NEG
tongue I-NEG
with O
little O
fur O
, O
hollow O
and O
rapid B-NEG
pulse I-NEG
, O
which O
is O
attributed O
to O
comsumption O
of O
both O
vital B-DNP
energy I-DNP
and O
body B-DNP
fluid I-DNP
by O
summer-heat O
evil O
. O
In O
this O
case O
, O

-DOCSTART- O

cool O
blood B-NEU
and O
alleviate O
edema B-NEG

-DOCSTART- O

To O
diffuse O
lung O
qi O
, O
dispel O
wind-damp B-NEG
, O
disperse O
swelling B-NEG
toxin I-NEG
. O

-DOCSTART- O

Inhibited O
urination B-NEU
, O
dribbling O
pain B-NEG
of O
urination O
, O
edema B-NEG
, O
bloody B-NEG
urine I-NEG
, O
damp-heat B-NEG
dysentery I-NEG
, O
asthma B-NEG
, O
sore B-NEG
swollen I-NEG
throat I-NEG
, O
toxin B-NEG
swelling I-NEG
of O
sores O
, O
wind-damp B-NEG
pain I-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
bleeding B-NEG
knife O
wound O
. O

-DOCSTART- O

Promoting O
phagocytosis O
of O
macrophage O
. O

-DOCSTART- O

arrest O
vomiting B-NEG

-DOCSTART- O

Urinary B-DNP
systems I-DNP
, O
Urinary B-DNP
system I-DNP
health I-DNP

-DOCSTART- O

palpitation B-NEG

-DOCSTART- O

To O
regulate O
cold B-NEU
and O
heat B-NEU
, O
regulate O
the O
functions B-NEU
of I-NEU
the I-NEU
stomach I-NEU
and O
lower O
down O
the O
adverse O
rising O
energy O
. O

-DOCSTART- O

difficulty B-NEG
in I-NEG
urination I-NEG
and I-NEG
defecation I-NEG
; O
constipation B-NEG
and O
ischuria B-NEG

-DOCSTART- O

To O
disperse O
accumulation O
, O
disinhibit O
diaphragm B-DNP
, O
precipitate O
heat B-NEG
toxin I-NEG
. O

-DOCSTART- O

To O
reduce O
swelling B-NEG
and O
promote O
healing O
. O

-DOCSTART- O

carbuncle B-NEG
and O
cellulitis B-NEG
of O
the O
back O
; O

carbuncle B-NEG
on O
the O
back O

-DOCSTART- O

abdominal B-NEG
mass I-NEG
; O
mass B-NEG
in I-NEG
the I-NEG
abdomen I-NEG

-DOCSTART- O

( O
1) O
wind-warm B-NEG
; O
wind-warm B-NEG
pathogen I-NEG
( O
1 O
) O
wind B-NEG
and O
warm O
blended O
as O
a O
pathogenic O
factor O
. O
( O
2 O
) O
wind-warm B-NEG
syndrome I-NEG
acute O
febrile B-NEG
diseases I-NEG
caused O
by O
wind-warm B-NEG
pathogene I-NEG
occurring O
in O
winter O
and O
spring O
, O
characterized O
by O
chills B-NEG
and O
fever B-NEG
, O
thirst B-NEG
sweating I-NEG
, O
cough B-NEG
and O
headache B-NEG
in O
the O
initial O
stage O
, O
and O
then O
, O
delirium B-NEG
and O
maculation B-NEG
in O
the O
following O
stage O
. O

-DOCSTART- O

For O
the O
treatment O
of O
obesity B-NEG
. O

-DOCSTART- O

These O
cross-links O
result O
in O
apoptosis B-POS
and O
cell B-NEG
growth I-NEG
inhibition I-NEG
. O

-DOCSTART- O

move O
blood B-NEU

-DOCSTART- O

breast B-NEG
abscess I-NEG
; O
acute B-NEG
mastitis I-NEG

-DOCSTART- O

Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Others O
, O
Protective O
immunity B-NEU
, O
Overall O
CVD B-NEG

-DOCSTART- O

Mucosal B-NEG
Melanoma I-NEG

-DOCSTART- O

However O
, O
like O
other O
antihypertensives O
, O
they O
all O
have O
to O
be O
self-administered O
daily O
and O
don't O
provide O
a O
good O
solution O
for O
improving O
patient O
compliance O
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Energy O
/ O
food O
intake O
( O
apetite O
/ O
satiety O
) O
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Endocrine B-DNP
system I-DNP
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

Treatment O
of O
anorexia B-NEG
, O
lassitude B-NEG
and O
loose B-NEG
stools I-NEG
in O
deficiency B-NEG
syndrome I-NEG
of I-NEG
the I-NEG
spleen I-NEG
, O
hysteria B-NEG
in O
women O
. O

-DOCSTART- O

move O
Gi O
( O
Qi O
) O
and O
break O
blood B-DNP

-DOCSTART- O

To O
desolve O
stagnation B-NEG
; O

To O
stop O
bleeding B-NEG
; O

To O
modulate O
period O

-DOCSTART- O

Cholangiocarcinoma B-NEG

-DOCSTART- O

This O
is O
damp-arthritis B-NEG
caused O
by O
apoplectoid B-NEG
syndrome I-NEG
. O

-DOCSTART- O

extinguish O
wind B-NEG
and O
stabilize O
fright O

-DOCSTART- O

Treament O
of O
cough B-NEG
, O
sore B-NEG
throat I-NEG
and O
hoarseness B-NEG
of I-NEG
voice I-NEG
due O
to O
heat B-NEG
in O
the O
lung O
, O
epigastic B-NEG
pain I-NEG
due O
to O
stagnation B-NEG
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O

Gastroesophageal B-NEG
Reflux I-NEG
Disease I-NEG

-DOCSTART- O

stop O
bleeding B-NEG

-DOCSTART- O

vomiting B-NEG
and O
regurgitation B-NEG

-DOCSTART- O

warm O
the O
kidney B-DNP

-DOCSTART- O

Purging O

-DOCSTART- O

Antiviral O
Treatment O
of O
Chronic B-NEG
Hepatitis I-NEG
B I-NEG

-DOCSTART- O

dissipate O
blood B-DNP

-DOCSTART- O

white B-NEG
vaginal I-NEG
discharge I-NEG
; O
leukorrhea B-NEG

-DOCSTART- O

Hydrocortisone O
binds O
to O
the O
cytosolic O
glucocorticoid O
receptor O
and O
promotes O
protein B-NEU
catabolism I-NEU
, O
gluconeogenesis B-NEU
, O
capillary B-NEU
wall I-NEU
stability I-NEU
, O
renal B-NEU
excretion I-NEU
of I-NEU
calcium I-NEU
, O
and O
suppresses O
immune B-NEU
and I-NEU
inflammatory I-NEU
responses I-NEU
. O

Polymyxin O
B O
sulfate O
interacts O
with O
the O
lipopolysaccharide O
of O
the O
cytoplasmic O
outer O
membrane O
of O
Gram-negative O
bacteria O
, O
altering O
membrane B-NEU
permeability I-NEU
and O
causing O
cell B-NEG
death I-NEG
. O

Chloramphenicol O
reversibly O
binds O
to O
the O
L16 O
protein O
of O
the O
50S O
subunit O
of O
bacterial O
ribosomes O
, O
thus O
inhibits O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

As O
GABA O
is O
an O
inhibitory O
neurotransmitter O
, O
this O
results O
in O
increased O
inhibition O
of O
the O
ascending O
reticular B-NEU
activating I-NEU
system I-NEU
. O

-DOCSTART- O

Diagnostic O
agent O
for O
radionuclide O
myocardial O
perfusion O
imaging O
( O
MPI O
) O

-DOCSTART- O

Ulcerative B-NEG
Colitis I-NEG

-DOCSTART- O

Retention O
of O
milk O
in O
babies O
, O
profuse O
sputum B-NEG
and O
infantile B-NEG
convulsions I-NEG
. O

-DOCSTART- O

Prevent O
pregnancy B-NEU

-DOCSTART- O

1 O
Treatment O
of O
skin B-NEG
infection I-NEG
, O
sorethroat B-NEG
, O
erysipelas B-NEG
, O
appendicitis B-NEG
, O
etc O
. O
Recently O
also O
used O
for O
leptospirosis B-NEG
. O
2 O
Treatment O
of O
conjunctivitis B-NEG
. O
Recently O
used O
for O
acute B-NEG
and I-NEG
chronic I-NEG
conjunctivitis I-NEG
, O
trachoma B-NEG
, O
keratitis B-NEG
, O
corneal B-NEG
ulcer I-NEG
, O
etc O
. O
, O
orally O
or O
toptically O
. O
diarrhea B-NEG
and O
dysentery B-NEG
of O
dampness-heat O
type O
, O
skin B-NEG
lesions I-NEG
of O
dampness O
type O
, O
etc O
. O

-DOCSTART- O

Alzheimer B-NEG
Disease I-NEG

-DOCSTART- O

To O
clear O
liver B-DNP
and O
brighten O
eyes B-DNP
. O

-DOCSTART- O

relieve O
toxicity B-NEG

-DOCSTART- O

white B-NEG
vaginal I-NEG
discharge I-NEG
; O
leukorrhea B-NEG

-DOCSTART- O

damp B-NEG
Pi I-NEG
syndrome I-NEG
; O
arthritis B-NEG
due O
to O
dampness B-NEU
; O
damp B-NEG
impediment O
[ O
blockage B-NEG
] O

-DOCSTART- O

cold B-NEG
sweating I-NEG
at O
night O

-DOCSTART- O

T'aeyang B-NEG
meridian I-NEG
affected O
by O
the O
wind O
; O
invasion O
of O
wind O
pathogen O
in O
T'aeyang B-NEG
meridian I-NEG

-DOCSTART- O

Thin B-NEG
Eyebrow I-NEG

-DOCSTART- O

a O
disease B-NEG
with O
pain B-NEG
and O
cold B-NEG
in I-NEG
the I-NEG
joints I-NEG

-DOCSTART- O

Diabetes B-NEG
Mellitus I-NEG

-DOCSTART- O

To O
dissipate O
cold B-NEG
and O
relieve O
pain B-NEG
, O
resolve O
toxin O
and O
disinhibit O
damp B-NEG
. O

-DOCSTART- O

alleviate O
edema B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

This O
means O
no O
rash B-NEG
formation O
after O
0305 O
days O
of O
fever B-NEG
. O

-DOCSTART- O

To O
supplement O
kidney B-DNP
and O
boost O
essence O
, O
warm O
lung B-DNP
and O
settle O
asthma B-NEG
, O
moisten O
intestines B-DNP
and O
free O
stool B-NEU
. O

-DOCSTART- O

Stagnation O
of O
liver-qi O
, O
abnormal B-NEG
relation I-NEG
between O
spleen O
and O
stomach O
, O
sensation B-NEG
of I-NEG
fullness I-NEG
and O
obstruction B-NEG
over O
chest O
and O
diaphragm O
, O
distension B-NEG
at O
hypochondriac O
regions O
, O
stomach-ache B-NEG
, O
gastric B-NEG
upset I-NEG
, O
eructation B-NEG
, O
acid B-NEG
eructation I-NEG
, O
nausea B-NEG
and O
vomiting B-NEG
. O

-DOCSTART- O

10-Gingerol O
, O
a O
component O
of O
Rikkunshito O
, O
improves O
cisplatin-induced O
anorexia B-NEG
by O
inhibiting O
acylated O
ghrelin O
degradation O
. O

-DOCSTART- O

Exciting O
the O
intestinal O
smooth O
muscles O
in O
vivo O
or O
in O
vitro O
, O
and O
relaxing O
the O
uterus B-DNP
of O
guinea-pigs O
in O
vitro O
. O

-DOCSTART- O

malaria B-NEG
; O
malarial B-NEG
disorder I-NEG
malaria B-NEG
and O
other O
disease O
characterized O
by O
intermittent O
rigor B-NEG
, O
high O
fever B-NEG
and O
sweating B-NEG
. O

-DOCSTART- O

phlegm-retention B-NEG
syndrome I-NEG
; O
congested O
fluids O
; O
retention O
of O
phlegm I-NEG
and O
fluid O
( O
1 O
) O
morbid O
conditions O
characterized O
by O
accumulation O
of O
dampness O
as O
a O
pathological O
product O
resulting O
from O
dysfunction O
of O
the O
lung B-DNP
, O
spleen B-DNP
md O
kidney B-DNP
or O
from O
disturbance O
of O
water O
circulation O
in O
the O
passage O
of O
Triple O
Ch'o( O
. O
The O
thicker O
dampness O
is O
called O
phlegm B-NEG
, O
while O
the O
thinner O
fluid O
. O
Retention O
of O
phlegm B-NEG
and O
fluid O
can O
give O
rise O
to O
various O
diseases O
, O
one O
of O
the O
four O
kinds O
of O
fluid O
retention O
. O
( O
2 O
) O
a O
morbid O
condition O
due O
to O
fluid O
retention O
in O
the O
stomach B-DNP
and O
intestines B-DNP
. O

-DOCSTART- O

Therapeutic O
effects O
of O
Saireito O
( O
chai-ling-tang O
) O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
on O
lymphedema B-NEG
caused O
by O
radiotherapy O
: O
a O
case O
series O
study O
. O

-DOCSTART- O

tetanus B-NEG

-DOCSTART- O

fluid B-NEG
retention I-NEG
; O

phlegm B-NEG
and O
retained B-NEG
fluid I-NEG
; O

congested B-NEG
fluids I-NEG

-DOCSTART- O

Heparin O
binds O
to O
antithrombin O
III O
to O
form O
a O
heparin-antithrombin O
III O
complex O
. O

-DOCSTART- O

Indicated O
in O
the O
treatment O
of O
moderate O
to O
severe B-NEG
pain I-NEG
. O
Consider O
for O
those O
prone O
to O
constipation B-NEG
or O
respiratory B-NEG
depression I-NEG
. O
Tramadol O
is O
used O
to O
treat O
postoperative O
, O
dental O
, O
cancer B-NEG
, O
and O
acute B-NEG
musculosketetal I-NEG
pain I-NEG
and O
as O
an O
adjuvant O
to O
NSAID O
therapy O
in O
patients O
with O
osteoarthritis B-NEG
. O

-DOCSTART- O

join O
sinews B-DNP
and O
bones B-DNP

-DOCSTART- O

Docetaxel O
binds O
to O
microtubules O
reversibly O
with O
high O
affinity O
, O
which O
stabilises O
microtubules O
and O
prevents O
depolymerisation O
from O
calcium O
ions O
, O
decreased B-NEG
temperature I-NEG
and O
dilution B-NEG
, O
preferentially O
at O
the O
plus O
end O
of O
the O
microtubule O
. O

Irinotecan O
, O
a O
prodrug O
, O
is O
converted O
to O
a O
biologically O
active O
metabolite O
7-ethyl-10-hydroxy-camptothecin O
( O
SN-38 O
) O
by O
a O
carboxylesterase-converting O
enzyme O
. O

SN-38 O
inhibits O
topoisomerase B-NEU
I I-NEU
activity I-NEU
by O
stabilizing O
the O
cleavable O
complex O
between O
topoisomerase O
I O
and O
DNA O
, O
resulting O
in O
DNA B-NEU
breaks I-NEU
that O
inhibit O
DNA B-NEU
replication I-NEU
and O
trigger O
apoptotic B-NEU
cell I-NEU
death I-NEU
. O

-DOCSTART- O

Lower O
the O
level O
of O
serum O
cholesterol O
and O
( O
B)-lipoprotein O
in O
experimental O
animals O
with O
hyperlipidemia. B-NEG
. O

-DOCSTART- O

This O
is O
having O
a O
lot O
of O
phlegm B-NEG
due O
to O
carbuncle B-NEG
and O
cellulites B-NEG
. O

-DOCSTART- O

exhaustion B-NEG
syndrome I-NEG
; O

consumption B-NEG
; O

exhaustion B-NEG
of I-NEG
strength I-NEG
; O

overstrain B-NEG
; O

asthenic B-NEG
disease I-NEG
; O

weakness B-NEG
and O
fatigue B-NEG

-DOCSTART- O

Essential B-NEG
Hypertension I-NEG

-DOCSTART- O

Enzalutamide O
is O
indicated O
for O
the O
treatment O
of O
patients O
with O
metastatic B-NEG
castration-resistant I-NEG
prostate I-NEG
cancer I-NEG
who O
have O
previously O
received O
docetaxel O
. O

-DOCSTART- O

Cough B-NEG
and O
shortness B-NEG
of I-NEG
breath I-NEG
, O
wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
itchy B-NEG
skin I-NEG
, O
innominate O
toxin B-NEG
swelling I-NEG
. O

-DOCSTART- O

glad O
and O
misten B-NEG
complexion I-NEG

-DOCSTART- O

To O
enrich O
the O
blood B-DNP
, O
to O
activate O
blood B-NEU
circulation I-NEU
, O
and O
to O
remove O
obstruction O
of O
the O
channels O
and O
collaterals O
. O

-DOCSTART- O

fetal O
irritability B-NEG
; O
threatened B-NEG
abortion I-NEG
; O
excessive O
fetal O
movements O
continuous O
moving O
of O
the O
fetus O
causing O
pain B-NEG
in O
the O
lower O
abdomen O
. O

-DOCSTART- O

night B-NEU
sweat I-NEU
and O
nocturnal B-NEU
emission I-NEU

-DOCSTART- O

Treatment O
of O
epistaxis B-NEG
, O
spitting B-NEG
of I-NEG
blood I-NEG
, O
hematuria B-NEG
, O
hematochezia B-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
traumatic B-NEG
bleeding I-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
. O

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Lipid O
profile O
, O
Quality O
of O
life O
, O
Overall O
CVD B-NEG
, O
Others O

-DOCSTART- O

Urinary B-DNP
system I-DNP
health I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
Urinary B-DNP
system I-DNP
health I-DNP
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
absorption B-NEU
, O
Urinary B-DNP
systems I-DNP
, O
Pregnancy B-DNP

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
Quality O
of O
life O
, O
absorption B-NEU
, O
Liver B-DNP
health I-DNP
, O
motility B-NEU
, O
Liver B-DNP
, O
Others O

-DOCSTART- O

CYT006-AngQb O
is O
a O
therapeutic O
vaccine O
designed O
to O
instruct O
the O
patient's O
immune B-NEU
system I-NEU
to O
produce O
a O
specific O
anti-angiotensin B-DNP
II I-DNP
antibody I-DNP
response I-DNP
. O

-DOCSTART- O

Photoaging B-NEG

-DOCSTART- O

toothache B-NEG

-DOCSTART- O

Diarrhea B-NEG
, O
dysentery B-NEG
, O
leprosy B-NEG
, O
scrotal B-NEG
wind I-NEG
, O
itchy B-NEG
skin I-NEG
. O

-DOCSTART- O

1 O
Treatment O
of O
rheumatism B-NEG
, O
trauma B-NEG
, O
headache B-NEG
, O
and O
other O
pains B-NEG
. O
Recently O
, O
also O
used O
for O
abdominal B-NEG
and O
biliary B-NEG
colics I-NEG
, O
and O
trigeminal B-NEG
neuralgia I-NEG
. O
2 O
Treatment O
of O
bronchial B-NEG
asthma I-NEG
and O
asthmatic B-NEG
bronchitis I-NEG
. O

-DOCSTART- O

Eye B-DNP
health I-DNP
, O
Hemostatic B-NEU
function I-NEU
, O
Eye B-DNP
, O
Diet B-NEG
cardiovascular I-NEG
disease I-NEG

-DOCSTART- O

Pain B-NEG

-DOCSTART- O

injury B-NEG
by O
knife O

-DOCSTART- O

Others O

-DOCSTART- O

To O
promote O
blood B-NEU
circulation I-NEU
, O
remove O
blood B-NEG
stasis I-NEG
and O
improve O
microcirculation B-NEU
. O

-DOCSTART- O

Chlorpheniramine O
binds O
to O
the O
histamine B-DNP
H1 O
receptor O
, O
which O
blocks O
the O
action B-NEU
of I-NEU
endogenous I-NEU
histamine I-NEU
, O
which O
subsequently O
leads O
to O
temporary O
relief O
of O
the O
negative O
symptoms O
brought O
on O
by O
histamine B-DNP
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation O
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU

-DOCSTART- O

harmonize O
acute B-NEG
and I-NEG
chronic I-NEG
disease I-NEG
of O
center O

-DOCSTART- O

warm O
the O
kidney B-DNP
and O
support O
Yang O

-DOCSTART- O

sore B-NEG
; O

pain B-NEG
; O

to O
ache B-NEG

-DOCSTART- O

Treatment O
of O
pains B-NEG
caused O
by O
blood B-NEG
stagnation I-NEG
. O

-DOCSTART- O

harmonize O
the O
stomach B-DNP

-DOCSTART- O

Eye B-DNP
, O
Blood B-NEU
pressure I-NEU
, O
Lipid O
profile O
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Inflammation B-NEG
, O
Urinary B-DNP
system I-DNP
health I-DNP
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
Urinary B-DNP
system I-DNP
health I-DNP
, O
absorption B-NEU
, O
UV O
protection O
, O
motility B-NEU
, O
Others O
, O
Urinary B-DNP
systems I-DNP
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
Hemostatic B-DNP
function I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Overall O
CVD B-NEG
, O
General O
skin B-DNP
health I-DNP
, O
Eye B-DNP
health I-DNP
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

Pectus B-NEG
Excavatum I-NEG

-DOCSTART- O

Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

GSK2190915 O
, O
a O
potent O
5-lipoxygenase-activating O
protein O
inhibitor O
, O
prevents O
the O
synthesis B-NEU
of I-NEU
leukotrienes I-NEU
and O
5-oxo-6,8,11,14-eicosatetraenoic O
acid O
( O
5-oxo-ETE O
) O
. O

-DOCSTART- O

cool O
the O
heart B-DNP

-DOCSTART- O

spitting O
bloody B-NEG
pus I-NEG
; O

cough B-NEG
with O
bloody B-NEG
pus I-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation O
, O
Reproductive B-DNP
systems I-DNP
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness O
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Endocrine B-DNP
system I-DNP
, O
Endurance B-POS
, O
Improvement O
of O
blood B-DNP
glucose I-DNP
levels I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Metabolism B-DNP
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Strength B-POS
and O
power B-POS
, O
Others O
, O
Quality O
of O
life O
, O
Protective O
immunity B-NEU
, O
Body O
fat O
deposition O
( O
total O
amount O

-DOCSTART- O

pain B-NEG
in O
throat O
and O
hypochondrium O

-DOCSTART- O

Portal B-NEG
Hypertension I-NEG

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Woman O
, O
Endocrine B-DNP
system I-DNP
, O
Lipid B-NEU
profile I-NEU
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
General O
woman O

-DOCSTART- O

Festering O
sore B-NEG
or O
abscess B-NEG
with O
inadequate O
drainage O
or O
initial O
granulation O
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
a O
pain B-NEG
in O
a O
waist O
and O
the O
side O
. O

-DOCSTART- O

The O
coldness B-NEG
of O
hands O
and O
feet O

-DOCSTART- O

it O
contains O
polysaccharide O
and O
polypeptide O
mainly O
. O

1 O
Inhibiting O
synthesis B-NEU
of I-NEU
DNA I-NEU
and I-NEU
RNA I-NEU
in O
cancer O
cells O
. O

2 O
Inhibiting O
sarcoma180 B-NEG
and O
Ehrlich-Ascites B-NEG
tumor I-NEG
in O
vitro O
. O

-DOCSTART- O

Polysaccharide-Containing O
Macromolecules O
in O
a O
Kampo O
( O
Traditional O
Japanese O
Herbal O
) O
Medicine O
, O
Hochuekkito O
: O
Dual O
Active O
Ingredients O
for O
Modulation O
of O
Immune O
Functions O
on O
Intestinal O
Peyer's B-NEU
Patches I-NEU
and O
Epithelial B-NEU
cells I-NEU
. O

-DOCSTART- O

This O
is O
bursting O
a O
carbuncle B-NEG
and O
cellulites B-NEG
after O
decaying O
. O

It O
is O
occurred O
in O
thick O
skin O
and O
region O
which O
have O
a O
lot O
of O
glandulae O
sebaceae O
and O
follicular O
. O

-DOCSTART- O

1 O
For O
cases O
attributive O
to O
deficiency O
and O
collapse O
of O
vital O
energy O
and O
downward O
flowing O
of O
essential O
substance,which O
manifest O
as O
prolonged O
discharge O
of O
rice-water O
like O
urine B-NEU
, O
pale B-NEG
complexion I-NEG
, O
fatigue B-NEG
, O
pale B-NEG
tongue I-NEG
and O
feeble B-NEG
pulse I-NEG
, O
add O
Fructus O
Corni O
to O
keep O
t O

-DOCSTART- O

To O
quicken O
blood B-DNP
and O
dispel O
stasis B-NEG
, O
regulate O
menstruation B-NEU
and O
relieve O
pain B-NEG
, O
nourish O
blood B-DNP
and O
quiet O
spirit O
, O
cool O
blood B-DNP
and O
disperse O
welling O
abscess B-NEG
. O

-DOCSTART- O

weakness B-NEG
of I-NEG
constitution I-NEG

-DOCSTART- O

headache B-NEG
due O
to O
adverse O
rising O
of O
phlegm B-NEG

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
cardiovascular B-NEG
disorders I-NEG
and O
inflammatory B-NEG
disorders I-NEG
( O
unspecified O
) O
. O

-DOCSTART- O

fever B-NEG
of O
juvenile O
Gamjeck O

-DOCSTART- O

